Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare REX AI Equity Premium Income ETF (AIPI) vs Nuwellis Inc (NUWE) Price & Performance

REX AI Equity Premium Income ETF
Nuwellis Inc

Price performance

Price movement over the last 24 hours

Key statistics

REX AI Equity Premium Income ETF vs Nuwellis Inc — how do they compare? REX AI Equity Premium Income ETF trades at $36.23, while Nuwellis Inc trades at $2.81 (market cap $1.15M). The key difference: REX AI Equity Premium Income ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.

AIPINUWE
Sector
Income / Options OverlayTechnology
52-Week High
$44.93$558.26
52-Week Low
$32.45$3.05
Market Cap
$1.15M
Enterprise Value
-$662.47K

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

REX AI Equity Premium Income ETF

AIPI trades at $37.10, up 1.87% with neutral technical signals. The ETF maintains a high weekly dividend distribution strategy, recently transitioning to weekly payouts. Technical analysis shows mixed signals with bullish moving averages but neutral oscillators, trading near key support at $37. Recent news highlights concerns about NAV erosion risk despite the attractive yield structure.

The outlook remains cautious due to structural limitations in the option-writing strategy that caps upside potential. While the ~34.8% yield appears attractive, sustainability depends heavily on AI market momentum. Investors face NAV erosion risk if technology sector performance falters, requiring careful monitoring of the fund's premium income strategy effectiveness.

Nuwellis Inc

NUWE trades at $3.29, up 4.44% today, but faces a bearish technical outlook with moving averages signaling a downtrend. The company reported a net loss of $17.52 million in 2025, with a negative net income margin of -217.22%, though it beat earnings expectations in two of the last three quarters. Recent news highlights expansion efforts, including new CEO Mike McCormick outlining strategic priorities and a $6 million public offering closed in June 2026 to support growth.

The outlook remains challenging due to persistent losses and high cash burn, but low valuation ratios like a P/E of 0.64 and P/B of 0.45 may attract value investors. Key risks include the need to achieve profitability and competitive pressures in the medical technology sector. Analyst sentiment is mixed with a 50% buy rating, suggesting cautious optimism amid fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About REX AI Equity Premium Income ETF

AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.

Read more on AIPI

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE